A Phase 2 interventional study of Active JNJ Drug and Placebo pill in Smoking Cessation, sponsored by Chengappa, K.N. Roy, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-15.
Sponsored by Chengappa, K.N. Roy, MD · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 921 studies in Smoking Cessation with a site in United States — 98 open to participants now, 127 under way, 7 of them phase 3. Smoking Cessation · United States.
Among the 921 studies in Smoking Cessation with a site in United States, this one is the 712th largest by enrollment of the 873 interventional ones that give a count, is one of 33 that started in 2014, is one of 105 in phase 2, and was the 414th registered.
1,583 studies on the registry are indexed under Smoking Cessation; 197 are open to participants now.
Browse Smoking Cessation studies →98 of the 921 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 135 Smoking Cessation studies recruiting now, 93 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
921 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 137 · Phase 3 91 · Phase 4 99
First in 1996; this study’s year is marked. 33 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 148 across the 873 interventional studies, 200 across the 45 observational. Of the 756 that completed or were terminated, 377 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 921 have an industry lead sponsor. The 10 most frequent:
Chengappa, K.N. Roy, MD is the lead sponsor of 2 studies on the registry; none are open to participants now.
Chengappa, K.N. Roy, MD has 1 study filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
56 of the studies in Smoking Cessation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT00591175Memorial Sloan Kettering Cancer CenterA Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 56 to your calendar (.ics) → With an account.
Among the 921 studies in Smoking Cessation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will assess a novel active drug vs. placebo on ability to reduce smoking and aid cessation during a one-week "practice" quit period for each condition in smokers with a high interest in quitting (i.e. crossover design). Medication effects on reducing withdrawal and cognitive impairment will help assess the mechanism to support quit smoking attempts.
We aim to test the proof of principal that an alpha-7 PAM drug, JNJ-39393406, promotes smoking cessation when compared to placebo. We have developed, tested, and validated an efficient Phase 2a screening procedure that optimally combines the validity of randomized clinical trials with the practicality of lab- based medication studies. Notably, it employs a within-subject, cross-over design comparing active versus placebo effects on quitting smoking to maximize statistical power without a large sample, in contrast to the large samples needed for between-groups randomized treatment conditions. Using this procedure, we will evaluate effects of JNJ-39393406 vs. placebo on short-term smoking abstinence in smokers who already have a high interest in quitting soon. We predict that, compared with placebo, JNJ-39393406 will increase days of abstinence, identifying initial evidence of efficacy for smoking cessation. Our main dependent measure is days of very stringent biochemically validated (expired CO\<5 ppm) 24-hr smoking abstinence, with post-quit withdrawal and cognitive function as secondary measures. Potential for adverse side-effects will be assessed at each visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy male and female dependent smokers wanting to quit soon
-
Exclusion Criteria:
Already enrolled in cessation program.
Epilepsy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
Drug: Active JNJ Drug · Drug: Placebo pill
Placebo pill used for one week quit attempt, as part of crossover design.
Drug: Active JNJ Drug · Drug: Placebo pill
200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
Also known as: JNJ-39393406
Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
Quit Status
Complete abstinence from smoking for 24 hr is counted as a "quit day" and is assessed daily from Mon-Fri for just one week, on the JNJ active drug and one week on placebo. This same Mon-Fri procedure for one week (only) is done for both drug phases. Total outcome in each drug condition therefore is number of quit days out of the five assessment days (range 0-5).
Time frame: up to one week each drug phase (0-5)
Minnesota Nicotine Withdrawal Scale (MNWS) During Attempt to Quit on Active JNJ Drug and on Placebo
Severity of withdrawal symptoms will be assessed with standard self-report measure of Minnesota Nicotine Withdrawal Scale (MNWS) each quit day during one week only on active JNJ, and each quit day during one week on placebo. Ratings are made on 0-100 visual analog scale, with 0="not at all" to 100="very much", and are averaged to create a total score also ranging from 0-100. Higher scores indicate more severe withdrawal.
Time frame: only on days quit while on JNJ or on placebo
Cognitive Function on Continuous Performance Task (CPT) for Those With CO<10 During First Assessment Day (Mon) of Attempt to Quit Smoking During Both JNJ and Plac Quit Periods
This measure of cognitive performance (mean of median speed of correct responding on computer keyboard to letters and numbers) was assessed only on Monday (day 1) of the 0-5 days during each drug/placebo condition. Data only from those shown to have CO\<10 ppm were analyzed, to confirm responding during abstinence while on drug/placebo condition. Cognitive testing consisted of standard Continuous Performance Task (CPT), on active JNJ and on placebo phases. This measure is assessed to determine potential mechanism of drug efficacy in relieving disrupted cognitive processing function caused by tobacco deprivation and withdrawal.
Time frame: first day during quit week on JNJ, and during quit week on placebo.
| Milestone | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active |
|---|---|---|
| Started | 18 | 18 |
| Completed | 17 | 15 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Milestone | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active |
|---|---|---|
| Started | 17 | 15 |
| Completed | 17 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Complete abstinence from smoking for 24 hr is counted as a "quit day" and is assessed daily from Mon-Fri for just one week, on the JNJ active drug and one week on placebo. This same Mon-Fri procedure for one week (only) is done for both drug phases. Total outcome in each drug condition therefore is number of quit days out of the five assessment days (range 0-5).
| number of days quit | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active |
|---|---|---|
| on JNJ | 0.5 ± 1.3 | 0.2 ± 0.6 |
| on placebo | 0.7 ± 1.5 | 0.5 ± 1.0 |
Severity of withdrawal symptoms will be assessed with standard self-report measure of Minnesota Nicotine Withdrawal Scale (MNWS) each quit day during one week only on active JNJ, and each quit day during one week on placebo. Ratings are made on 0-100 visual analog scale, with 0="not at all" to 100="very much", and are averaged to create a total score also ranging from 0-100. Higher scores indicate more severe withdrawal.
| units on a scale | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active |
|---|---|---|
| on active JNJ | 12.4 ± 8.1 | 24.0 ± 23.4 |
| on placebo | 15.5 ± 15.2 | 23.1 ± 19.8 |
This measure of cognitive performance (mean of median speed of correct responding on computer keyboard to letters and numbers) was assessed only on Monday (day 1) of the 0-5 days during each drug/placebo condition. Data only from those shown to have CO\<10 ppm were analyzed, to confirm responding during abstinence while on drug/placebo condition. Cognitive testing consisted of standard Continuous Performance Task (CPT), on active JNJ and on placebo phases. This measure is assessed to determine potential mechanism of drug efficacy in relieving disrupted cognitive processing function caused by tobacco deprivation and withdrawal.
| ms time of correct responding | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active |
|---|---|---|
| on active JNJ | 444.3 ± 69.3 | 443.3 ± 32.0 |
| on placebo | 434.2 ± 33.5 | 439.2 ± 28.0 |
Collected over Assessed over the 2 weeks of med use on each condition (active JNJ, or placebo) per participant and ending within 1 week post-participation.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| While on Active JNJ | 0/36 (0%) | 0/36 (0%) | 5/36 (13.9%) |
| While on Placebo | 0/36 (0%) | 0/36 (0%) | 3/36 (8.3%) |
| Event | While on Active JNJ | While on Placebo |
|---|---|---|
| self-reported nauseaGastrointestinal disorders | 3/36 | 0/36 |
| Abnormal EKGCardiac disorders | 1/36 | 0/36 |
| diarrheaGastrointestinal disorders | 1/36 | 0/36 |
| self-reported skin rashSkin and subcutaneous tissue disorders | 0/36 | 1/36 |
| swelling in feetMusculoskeletal and connective tissue disorders | 0/36 | 1/36 |
| body achesGeneral disorders | 1/36 | 0/36 |
| feeling of subjective panicGeneral disorders | 1/36 | 1/36 |
| heart racingCardiac disorders | 0/36 | 1/36 |
Healthy smokers interested in permanently quitting smoking within the next few months.
| Age, Categorical(Participants) | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 36 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active | Total |
|---|---|---|---|
| Female | 9 | 10 | 19 |
| Male | 9 | 8 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 18 | 18 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active | Total |
|---|---|---|---|
| United States | 18 | 18 | 36 |
| Fagerstrom Test of Nicotine Dependence (FTND) scale score(units on a scale) | Order 1--JNJ Active Then Plac | Order 2--Placebo Then JNJ Active | Total |
|---|---|---|---|
| Mean | 4.9 ± 1.5 | 4.9 ± 1.5 | 4.9 ± 1.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Nov 2014, a primary completion of Jul 2017 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JNJ-39393406
Chengappa, K.N. Roy, MD